Collateral for a security interest recorded Sep 14, 2022 (Vickers Venture Fund VI Pte. Ltd.).
Term ends Aug 9, 2030 · High confidence
20-year base term ends Mar 13, 2033
Held by Biosplice Therapeutics, Inc.
Filed May 1, 2018 as application 15/968,555 · Granted Sep 10, 2019
Base term, 20 years from filing · capped by a resolved terminal disclaimer
Today
2013
2033
Clock starts
Mar 13, 2013
Mar 13, 2013
Term ends
Aug 9, 2030
Aug 9, 2030
Granted
Sep 10, 2019
Sep 10, 2019
base term
after the term ends
fee events
Updated Nov 14, 2026 · includes USPTO assignment & status data published Nov 14, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
None
Term adjustment
No prosecution delay on this record.
Capped
Terminal disclaimer
Resolved from the filed document, referencing US 8,664,241, US 8,673,936, US 8,987,298, US 9,199,991, US 9,994,563.
1 of 2
Maintenance fees paid
Two maintenance fees can end this term early, the ones due 3.5 and 7.5 years from grant; the third one's grace period runs past the term end. This counts the ones the record shows paid.
10
Family applications on record here
Applications sharing this one's continuity chain whose file history this site holds. The family may have others.
This patent's term is its 20-year base term, with no adjustment for prosecution delay. A terminal disclaimer resolved from the filed document caps it earlier. 1 of 2 maintenance fees is paid so far. Confidence: High. from the record
How we calculated this date
One row per rule, each showing its own input and what it did to the date. A step we could not verify says so instead of resolving itself.
| Step | Input | Date after this step | Confidence |
|---|---|---|---|
| Base term, 20 years from filing | Clock starts Mar 13, 2013, when application 13/800,963, the earliest non-provisional in its chain, was filed (this one was filed May 1, 2018) | Mar 13, 2033 | High confidence |
| Continuity chain | Every parent in the chain resolved | no change | High confidence |
| Patent term adjustment | None on file | no change | High confidence |
| Terminal disclaimer cap | Disclaimer resolved from the filed document (refs US 8,664,241, US 8,673,936, US 8,987,298, US 9,199,991, US 9,994,563) | capped to Aug 9, 2030 | High confidence |
| Patent term extension | None on file | no change | High confidence |
| Fee events | 1 of 2 maintenance fees paid | In force | High confidence |
| Computed term end | The steps above, in order | Aug 9, 2030 | High confidence |
This family
| US 8,673,936 | In force Aug 2030 | Aug 2030 |
| US 8,664,241 | In force Aug 2030 | Aug 2030 |
| US 8,987,298 | In force Sep 2030 | Sep 2030 |
| US 9,199,991 | In force Aug 2030 | Aug 2030 |
| US 9,994,563 | In force Mar 2033 | Mar 2033 |
| US 10,407,425 | this patent Aug 2030 | Aug 2030 |
| US 10,947,228 | In force Aug 2030 | Aug 2030 |
| US 11,697,649 | In force Aug 2030 | Aug 2030 |
8 of 10 applications in this family shown, earliest filings first. The applications whose file history this site holds. The family may have others.
Assignments
Assignment documents as recorded at the USPTO, oldest first, with the reel and frame each was recorded at. A recorded assignment is a filed document, not a statement of current ownership, and the absence of a later one is not evidence that the last one still stands.
| Recorded | Assignor | Assignee | Conveyance |
|---|---|---|---|
| May 24, 2019 Reel 49277, frame 843 | Hood, John; Wallace, David Mark; Kc, Sunil Kumar | Samumed, LLC | Assignment of Assignor's Interest |
| Feb 23, 2021 Reel 55375, frame 764 | Hood, John; Wallace, David Mark; Kumar Kc, Sunil | Samumed, LLC | Assignment of Assignor's Interest |
| Mar 23, 2021 Reel 55693, frame 809 | Samumed, LLC | Biosplice Therapeutics, Inc. | Assignment of Assignor's Interest |
| Sep 14, 2022 reel/frame not recorded | Biosplice Therapeutics, Inc. | Vickers Venture Fund VI Pte. Ltd. | Security Interest |
| Sep 14, 2022 reel/frame not recorded | Biosplice Therapeutics, Inc. | Vickers Venture Fund VI (Plan) Pte. Ltd. | Security Interest |
| Sep 14, 2022 reel/frame not recorded | Biosplice Therapeutics, Inc. | Vickers-Splice Co.-Investment LLC | Security Interest |
| Sep 14, 2022 reel/frame not recorded | Biosplice Therapeutics, Inc. | Med-Pathways II Limited | Security Interest |
| Sep 14, 2022 Reel 61433, frame 786 | Biosplice Therapeutics, Inc. | Vickers Venture Fund VI Pte. Ltd.; Vickers Venture Fund VI (Plan) Pte. Ltd.; Vickers-Splice Co.-Investment LLC; Med-Pathways II Limited | Security Interest |
Sources
Google Patents · The patent document at USPTO · Assignment records at USPTO
USPTO account required: This application in Patent Center · USPTO's maintenance fee lookup
Maintenance fee events come from USPTO's own fee records. Its fee lookup asks for the patent number and the application number.
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
What's changing
Aug 2030
Term ends Aug 9, 2030. Maintenance fees still fall due before then
Disclaimer cap
This term is capped by a terminal disclaimer resolved from the filed document, referencing US 8,664,241, US 8,673,936, US 8,987,298, US 9,199,991, US 9,994,563.
Citations
25
later US patents cite this one
That is top 10% of utility patents granted in 2019 in our data, the only group it is compared against.
How we rank
Every date shows its work: the base term, any term adjustment or extension, any disclaimer cap, and the maintenance fee record, each with a confidence tier. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
In force means the term is running and no lapse is on record. It is not a finding that the patent is valid.